STOCK TITAN

Amgen (NASDAQ: AMGN) CEO has 2,079 shares withheld for taxes

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Amgen Inc. Chairman, CEO and President Robert A. Bradway reported a routine tax-withholding transaction in company stock. On 2026-05-07, 2,079 shares of Amgen common stock were withheld at $331.11 per share to satisfy tax obligations, not as an open-market sale.

Following this withholding, Bradway directly owns 505,160 shares of Amgen common stock. He also reports indirect holdings through related parties, including shares held by his spouse and in spousal GRAT and GRAT vehicles, reflecting additional indirect economic exposure to Amgen stock.

Positive

  • None.

Negative

  • None.
Insider Bradway Robert A
Role Chairman, CEO and President
Type Security Shares Price Value
Tax Withholding Common Stock 2,079 $331.11 $688K
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 505,160 shares (Direct, null); Common Stock — 60,060 shares (Indirect, By GRAT)
Footnotes (1)
  1. [object Object]
Tax-withholding shares 2,079 shares Code F tax-withholding disposition on 2026-05-07
Tax-withholding price $331.11 per share Value applied to 2,079 withheld shares
Direct holdings after transaction 505,160 shares Common stock held directly after 2026-05-07
Indirect holdings by spouse 29,940 shares Common stock held indirectly by spouse
Indirect holdings by spousal GRAT 60,060 shares Common stock held indirectly by spousal GRAT
Indirect holdings by GRAT 60,060 shares Common stock held indirectly by GRAT
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
Dividend Equivalents (DEs) financial
"These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"
Restricted Stock Units financial
"DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
GRAT financial
"nature_of_ownership": "By Spousal GRAT""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bradway Robert A

(Last)(First)(Middle)
ONE AMGEN CENTER DRIVE

(Street)
THOUSAND OAKS CALIFORNIA 91320-1799

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman, CEO and President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/07/2026F2,079D$331.11505,160(1)D
Common Stock60,060IBy GRAT
Common Stock60,060IBy Spousal GRAT
Common Stock29,940IBy Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
/s/ Robert A. Bradway05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Amgen (AMGN) CEO Robert Bradway report?

Robert A. Bradway reported a tax-withholding disposition of 2,079 Amgen common shares at $331.11 per share. These shares were withheld to cover tax obligations, rather than sold in the open market, and are reported as a Form 4 transaction.

How many Amgen (AMGN) shares does the CEO hold after this Form 4?

After the reported tax-withholding, Robert A. Bradway directly holds 505,160 shares of Amgen common stock. The filing also lists additional indirect holdings through his spouse and related GRAT entities, which represent further economic exposure beyond his direct ownership position.

Was the Amgen (AMGN) CEO’s Form 4 transaction a market sale?

No. The Form 4 identifies the transaction with code F, a tax-withholding disposition. This means 2,079 shares were delivered to cover exercise price or tax liabilities, rather than being sold on the open market, and is considered a routine administrative transaction.

What price per share was used in the Amgen (AMGN) CEO tax withholding?

The tax-withholding disposition used a price of $331.11 per Amgen common share for the 2,079 shares. This price is applied for the purpose of calculating the value of shares delivered to satisfy tax obligations associated with the underlying equity compensation.

What indirect Amgen (AMGN) shareholdings are reported for the CEO?

The filing lists indirect holdings in Amgen common stock by the CEO’s spouse and by spousal GRAT and GRAT entities. Reported post-transaction positions include 29,940 shares by spouse, 60,060 shares by spousal GRAT, and 60,060 shares by GRAT, in addition to his direct holdings.